Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Sci Rep
.
2024 Nov 6;14(1):26915.
doi: 10.1038/s41598-024-77480-w.
Authors
Aleksandr Gordeev
1
,
Andrei Vaal
2
,
Maria Puchkova
2
,
Iana Smirnova
2
,
Aleksandr Doronin
2
,
Anna Znobishcheva
2
,
Daria Zhmudanova
2
,
Aleksei Aleksandrov
2
,
Mikhail Sukchev
2
,
Evgeny Imyanitov
3
,
Valery Solovyev
2
,
Pavel Iakovlev
2
Affiliations
1
JSC BIOCAD, St.-Petersburg, Russia.
[email protected]
.
2
JSC BIOCAD, St.-Petersburg, Russia.
3
Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia.
PMID:
39505987
PMCID:
PMC11541495
DOI:
10.1038/s41598-024-77480-w
No abstract available
Publication types
Published Erratum